Breast Cancer Follow-Up Tests After Treatment: Mammograms, MRI, Blood Tests and When Scans Are Needed

Finishing breast cancer treatment does not mean that medical care suddenly stops. The next phase is follow-up care: regular appointments, physical examinations and breast imaging. The exact plan depends on the original cancer, its stage, treatment received and whether ongoing medicines need monitoring. This guide supports the Breast Cancer Treatment in India pathway and the diagnosis explainer.

Breast cancer follow-up has several purposes. The first is to look for signs that the cancer has returned. The second is to monitor side effects that may continue after treatment. The third is to manage long-term health issues related to cancer treatment and general health. For some patients, follow-up also includes monitoring long-term medicines such as endocrine therapy. A follow-up appointment is not simply a cancer scan. It is a broader assessment of your health after treatment.

A visit may be quite straightforward. Your doctor may ask about new breast changes, pain, swelling, shortness of breath, bone or back pain, neurological symptoms, medication side effects, menopausal symptoms, arm swelling or lymphedema, and general health. A physical examination of the treated breast or chest wall, the remaining breast, surgical area and lymph-node regions may then be performed. The exact examination depends on the treatment history.

There is no universal schedule. Frequency depends on the type of breast cancer, original stage, treatment received, current medication, treatment-related complications, overall health and new symptoms. Visits are often every 3–6 months initially, becoming less frequent as more time passes. After five years, annual visits are common, although individual plans vary.

If you had a lumpectomy or other breast-conserving surgery, you generally continue mammographic surveillance. The treated breast looks different after surgery, and radiation can also change the tissue. The first post-treatment mammogram — generally around 6–12 months after surgery and radiation — establishes a new baseline for future comparison.

It gives the radiologist a new reference point. The breast may have scar tissue, surgical changes, skin thickening, radiation-related changes or architectural distortion. These findings can make interpretation different from a routine screening mammogram. Future images can then be compared with the post-treatment baseline to recognise whether a finding is stable or has changed.

If the entire breast has been removed, routine mammography of that side is generally no longer necessary because there is little or no breast tissue to image. If only one breast was removed, the remaining breast usually continues to need mammographic surveillance. Nipple-sparing or skin-sparing procedures can require individualised advice because some breast tissue may remain. After bilateral mastectomy, routine mammography is generally not required, but chest-wall examination continues. A new lump, swelling or skin change should still be evaluated.

For many survivors who retain breast tissue, annual mammography is part of ongoing surveillance. Some patients are advised to have imaging more frequently for a period of time. The plan should be based on your surgery, remaining breast tissue, age, risk factors and previous findings.

A diagnostic mammogram is performed when there is a specific concern — a new lump, focal pain, skin or nipple changes, or an abnormal screening mammogram. Additional views and ultrasound may be used. Ultrasound can help distinguish certain fluid-filled structures from solid masses and is often used alongside mammography rather than as a replacement. If a suspicious abnormality remains, a biopsy may be recommended.

Breast MRI is a powerful tool, but it is not necessary for every patient who has previously had breast cancer. It may be considered for high inherited risk, BRCA or other pathogenic variants, strong family history, age at diagnosis, breast density, particular imaging findings or clinical concern. MRI can also produce findings that require additional imaging or biopsy, so it is not simply a more detailed mammogram.

After lumpectomy, MRI may help when mammography and ultrasound cannot clearly characterise a new finding. It should not automatically replace mammography in routine follow-up. After mastectomy, MRI is not routinely required. A new lump or change along the chest wall or reconstruction may be investigated with ultrasound, MRI, mammography of remaining tissue or other imaging.

For patients who have completed treatment for early-stage breast cancer and have no symptoms or concerning findings, routine PET-CT is generally not part of standard surveillance. Routine bone scans, liver imaging and chest imaging have not been shown to improve survival or quality of life in asymptomatic patients after treatment for stages I–III breast cancer. That does not mean PET-CT is never useful. It can be very useful when there is a specific clinical question.

Advanced imaging may be considered for a suspicious new lesion, persistent unexplained symptoms, a concerning examination, abnormal conventional imaging, suspected distant spread, or monitoring known metastatic cancer. A CT scan may be appropriate if there is a specific concern involving the lungs, liver or other organs. Bone scans may be used for persistent unexplained bone pain. See the recurrence guide if new findings need investigation.

Blood tests can be useful in many situations, but they are not a universal screening tool for recurrence. Routine blood tests and tumour-marker testing are not generally recommended as the main surveillance method for asymptomatic patients treated for early-stage breast cancer. They may still be ordered to investigate symptoms or monitor organ function.

CA 15-3 and CEA are blood markers that may be associated with breast cancer. For routine surveillance of asymptomatic patients after early-stage treatment, these markers are not generally used as a substitute for clinical assessment and appropriate imaging. A doctor may use tumour markers in selected situations, particularly in known advanced disease. Normal blood results do not prove that breast cancer has not returned. Many recurrences do not produce abnormalities on routine blood tests.

These symptoms do not automatically mean recurrence. There can be many other explanations. But they deserve assessment. A normal mammogram is reassuring, but it cannot detect every possible recurrence — for example in the chest wall after mastectomy, in lymph nodes, or in another part of the body.

BI-RADS is a standardised system used to describe breast imaging findings. BI-RADS 3 is considered probably benign and generally leads to short-interval imaging follow-up rather than immediate biopsy. BI-RADS 4 is a suspicious abnormality for which biopsy may be recommended. BI-RADS 5 is highly suggestive of malignancy and generally requires tissue diagnosis. A BI-RADS score is an imaging assessment. It is not the same as a cancer stage.

Surgery and radiation can produce scarring, architectural distortion, skin thickening, fluid collections, fat necrosis and changes around the surgical site. Some of these findings can look concerning on imaging. Comparison with previous scans is therefore extremely valuable. Fat necrosis involves damaged fatty tissue. It can feel like a lump and may appear suspicious. Additional imaging or biopsy may be needed to distinguish it from recurrence. A new lump after treatment should be assessed rather than assumed to be cancer.

Genetic testing is not a routine follow-up scan. Some survivors may benefit from genetic assessment because of age at diagnosis, family history, bilateral disease, male breast cancer in the family, triple-negative disease in certain age groups or a known familial mutation. If a pathogenic inherited mutation is identified, the long-term surveillance plan may change.

Patients who received certain HER2-targeted treatments may need cardiac monitoring. Patients on endocrine therapy may discuss hot flashes, joint pain, bone health, menstrual changes, sexual health and adherence. Aromatase inhibitors can contribute to bone loss; a DEXA scan is a bone-health test, not a recurrence scan.

Keep more than the discharge summary. A complete record should include the original biopsy and pathology, ER, PR, HER2, Ki-67, genetic testing if performed, operative and lymph-node reports, margin status, chemotherapy, targeted therapy, immunotherapy and hormone-therapy details, the radiation summary, and imaging files — not just written reports. See the international-patient guide and the cost guide.

Some international patients return to the same Indian hospital for follow-up. Others arrange periodic consultations in India while receiving routine care closer to home. Some aspects can be handled remotely — new imaging, pathology, blood reports, medication history and symptoms — but a new lump or swelling should not wait for an online consult alone. Teams in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad can confirm the schedule. Hospitals in Delhi NCR and Mumbai can store or review imaging files.

A survivorship care plan summarises the diagnosis, stage, treatment received, follow-up schedule, recommended imaging, possible late effects, medication plan and contact information. It is particularly useful if you will be returning to another country.

Routine surveillance is performed because your treatment history means you should be monitored — for many patients, clinical follow-up and mammography when breast tissue remains. Tests for symptoms are ordered because something has changed: a new lump leads to examination, mammogram or ultrasound, and possibly biopsy. Tests for treatment effects are performed because a particular treatment can affect another part of the body, such as cardiac monitoring after certain systemic treatments. That is why two survivors may have very different schedules.

Follow-up commonly includes medical appointments, physical examination and mammography when breast tissue remains. Other tests are added when they answer a specific question.

Usually yes if breast tissue remains. After breast-conserving surgery, the first mammogram is generally about 6–12 months after surgery and radiation.

The removed breast generally does not require routine mammography. The remaining breast usually continues to need surveillance.

Not routinely if there are no symptoms or clinical findings suggesting recurrence.

They are not generally the main surveillance method for asymptomatic early-stage patients.

It may be recommended for selected patients based on risk, genetics, density or a specific clinical finding.

Contact your doctor. It may have several causes, including treatment-related changes, but it should be assessed.

Yes. Mammography cannot detect every recurrence. Report new or persistent symptoms even after a normal result.

Follow-up continues for years. Appointments are usually more frequent at first and become less frequent over time.

Follow-up is not about having every possible scan. For many people treated for early-stage breast cancer, it includes regular clinical visits and mammography when breast tissue remains. Routine PET-CT, CT, bone scans and extensive blood testing are generally not required when there are no symptoms. A new lump, persistent pain, swelling, skin change, breathing problem, unexplained weight loss or neurological symptom should still be discussed. International patients should keep the complete cancer record — pathology, imaging files, operative reports, chemotherapy records, radiation summary and medication history.

• Breast Cancer Treatment in India
• Diagnosis
• Recurrence
• Hormone therapy side effects
• Chemotherapy side effects
• Targeted therapy side effects
• Radiation side effects
• Breast-conserving surgery doctors
• Mastectomy doctors
• Reconstruction doctors
• Chemotherapy doctors
• Hormone therapy doctors
• Targeted therapy doctors
• Immunotherapy doctors
• International patients